Oncoinvent's Radspherin® shows strong potential in ovarian cancer trial

Oncoinvent ASA reported encouraging final 24-month follow-up data from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. Of the 10 patients who received the highest recommended dose of 7 MBq Radspherin® after dose escalation, only one experienced peritoneal recurrence, maintaining a 10% peritoneal recurrence rate. The overall recurrence rate, including two additional patients with lymph node metastases, was 30%, significantly lower than the 55-60% expected in similar populations with standard care.

Radspherin® is an investigational radiopharmaceutical designed to eliminate post-surgery micro-metastases and delay peritoneal recurrence. The RAD-18-001 trial enrolled 21 patients across Norway, Belgium, and Spain, evaluating dosing, safety, tolerability, and efficacy signals following complete surgical resection.

Chief executive Oystein Soug emphasized these results conclude their Phase 1 program, fueling advancement into Phase 2, with interim results anticipated next year. Dr. Luis Chiva, the principal investigator, noted that limiting new recurrences to lymph nodes, which are associated with longer survival compared to peritoneal relapses, is particularly promising.